Ji Shiqi, Su Xiaolin, Zhang Haijian, Han Zhixing, Zhao Yuqian, Liu Qingjun
Department of Urology, Beijing Ditan Hospital Capital Medical University, Capital Medical University, Beijing 100015, P.R. China.
Department of Emergency, Beijing First Hospital of Integrated Chinese and Western Medicine, Beijing 100021, P.R. China.
Oncol Lett. 2019 Feb;17(2):2400-2408. doi: 10.3892/ol.2018.9871. Epub 2018 Dec 28.
In recent years, renal cell carcinoma (RCC) has exhibited an increasing incidence and mortality rate worldwide. Accumulating evidence has identified that microRNAs (miRNAs) function as negative or positive regulators of many malignant tumors; however, the roles of miR-372 in RCC remain unclear. The focus of the present study was the functions of miR-372 in RCC metastasis and EMT. Data revealed that miR-372 expression levels were significantly downregulated in RCC tissue samples and cells. Moreover, the decreased expression levels were strongly associated with the poor survival rates and adverse clinical characteristics of RCC patients. Accordingly, miR-372 overexpression markedly inhibited RCC cell invasion, migration and EMT. In terms of the potential mechanisms, , the expression of which was inversely correlated with miR-372 expression in RCC, was identified as a direct functional target of miR-372. Notably, silence exerted suppressive functions in RCC cells, being similar to the effects of miR-372 overexpression. In conclusion, findings of this study indicate that miR-372 repressed RCC EMT and metastasis via targeting , suggesting that the miR-372/ axis may be therapeutic biomarkers for RCC.
近年来,肾细胞癌(RCC)在全球范围内的发病率和死亡率呈上升趋势。越来越多的证据表明,微小RNA(miRNA)作为许多恶性肿瘤的负性或正性调节因子发挥作用;然而,miR-372在RCC中的作用仍不清楚。本研究的重点是miR-372在RCC转移和上皮-间质转化(EMT)中的功能。数据显示,RCC组织样本和细胞中miR-372的表达水平显著下调。此外,表达水平的降低与RCC患者的低生存率和不良临床特征密切相关。因此,miR-372过表达显著抑制RCC细胞的侵袭、迁移和EMT。就潜在机制而言,被确定为miR-372的直接功能靶点,其表达与RCC中miR-372的表达呈负相关。值得注意的是,沉默在RCC细胞中发挥抑制作用,类似于miR-372过表达的效果。总之,本研究结果表明,miR-372通过靶向抑制RCC的EMT和转移,提示miR-372/轴可能是RCC的治疗生物标志物。